{"pmid":32330482,"title":"Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.","text":["Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.","Antiviral Res","Bray, Mike","Rayner, Craig","Noel, Francois","Jans, David","Wagstaff, Kylie","32330482"],"journal":"Antiviral Res","authors":["Bray, Mike","Rayner, Craig","Noel, Francois","Jans, David","Wagstaff, Kylie"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330482","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.antiviral.2020.104805","source":"PubMed","weight":0,"_version_":1664996914856198144,"score":8.518259,"similar":[{"pmid":32247592,"pmcid":"PMC7132516","title":"Author reply to Letters to the Editor \"COVID-19 pneumonia in Taiwan\".","text":["Author reply to Letters to the Editor \"COVID-19 pneumonia in Taiwan\".","J Formos Med Assoc","Cheng, Shao-Chung","Fan Chiang, Yu-Long","Huang, Chia-Husn","Hsu, Yuan-Nian","32247592"],"journal":"J Formos Med Assoc","authors":["Cheng, Shao-Chung","Fan Chiang, Yu-Long","Huang, Chia-Husn","Hsu, Yuan-Nian"],"date":"2020-04-06T11:00:00Z","year":2020,"_id":"32247592","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.jfma.2020.03.011","source":"PubMed","weight":0,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664637850773094401,"score":104.954285},{"pmid":32249110,"title":"Author reply to Letters to the Editor \"CT chest findings in coronavirus disease (COVID-19)\".","text":["Author reply to Letters to the Editor \"CT chest findings in coronavirus disease (COVID-19)\".","J Formos Med Assoc","Chang, Yuan-Chia","Yang, Chin-Hua","Chien, Yu-Chan","Hsu, Yuan-Nian","32249110"],"journal":"J Formos Med Assoc","authors":["Chang, Yuan-Chia","Yang, Chin-Hua","Chien, Yu-Chan","Hsu, Yuan-Nian"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32249110","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.jfma.2020.03.012","source":"PubMed","weight":0,"_version_":1663352136220540928,"score":90.839745},{"pmid":32251768,"title":"The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.","text":["The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.","Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect approximately 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.","Antiviral Res","Caly, Leon","Druce, Julian D","Catton, Mike G","Jans, David A","Wagstaff, Kylie M","32251768"],"abstract":["Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect approximately 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans."],"journal":"Antiviral Res","authors":["Caly, Leon","Druce, Julian D","Catton, Mike G","Jans, David A","Wagstaff, Kylie M"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251768","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.antiviral.2020.104787","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352136233123840,"score":83.38615},{"pmid":32324443,"title":"Response to Letters to the Editor about the Safe Handling of Containers of Expressed Human Milk in all Settings During the SARS-CoV-2 (COVID-19) Pandemic.","text":["Response to Letters to the Editor about the Safe Handling of Containers of Expressed Human Milk in all Settings During the SARS-CoV-2 (COVID-19) Pandemic.","J Hum Lact","Marinelli, Kathleen Ann","Lawrence, Robert Michael","32324443"],"journal":"J Hum Lact","authors":["Marinelli, Kathleen Ann","Lawrence, Robert Michael"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324443","week":"202017|Apr 20 - Apr 26","doi":"10.1177/0890334420924351","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664895932650487810,"score":61.79653},{"pmid":32247325,"title":"Monitoring the COVID-19 epidemic in the context of widespread local transmission.","text":["Monitoring the COVID-19 epidemic in the context of widespread local transmission.","Lancet Respir Med","Garcia-Basteiro, Alberto L","Chaccour, Carlos","Guinovart, Caterina","Llupia, Anna","Brew, Joe","Trilla, Antoni","Plasencia, Antoni","32247325"],"journal":"Lancet Respir Med","authors":["Garcia-Basteiro, Alberto L","Chaccour, Carlos","Guinovart, Caterina","Llupia, Anna","Brew, Joe","Trilla, Antoni","Plasencia, Antoni"],"date":"2020-04-06T11:00:00Z","year":2020,"_id":"32247325","week":"202015|Apr 06 - Apr 12","doi":"10.1016/S2213-2600(20)30162-4","source":"PubMed","topics":["Prevention","Transmission"],"weight":1,"_version_":1664637850746880000,"score":57.94908}]}